• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Initial combination therapy of macitentan and tadalafil in pulmonary arterial hypertension.马昔腾坦与他达拉非联合治疗肺动脉高压。
Eur Respir J. 2020 Sep 3;56(3). doi: 10.1183/13993003.00673-2020. Print 2020 Sep.
2
Randomized Trial of Macitentan/Tadalafil Single-Tablet Combination Therapy for Pulmonary Arterial Hypertension.随机试验：马西替坦/他达拉非单片复方制剂治疗肺动脉高压。
J Am Coll Cardiol. 2024 Jan 30;83(4):473-484. doi: 10.1016/j.jacc.2023.10.045.
3
Combination Therapy of Pulmonary Arterial Hypertension with Vardenafil and Macitentan Assessed in a Human Ex Vivo Model.肺动脉高压的伐地那非和马昔腾坦联合治疗在人体体外模型中的评估。
Cardiovasc Drugs Ther. 2019 Jun;33(3):287-295. doi: 10.1007/s10557-019-06868-y.
4
Plasma Drug Concentrations in Patients with Pulmonary Arterial Hypertension on Combination Treatment.肺动脉高压患者联合治疗的血浆药物浓度。
Respiration. 2017;94(1):26-37. doi: 10.1159/000470916. Epub 2017 May 12.
5
Stability Indicating RP-HPLC-DAD method for simultaneous estimation of tadalafil and macitentan in synthetic mixture for treatment of pulmonary arterial hypertension.用于治疗肺动脉高压的合成混合物中他达拉非和马昔腾坦同时定量的稳定性指示反相高效液相色谱-二极管阵列检测法。
Ann Pharm Fr. 2024 May;82(3):464-472. doi: 10.1016/j.pharma.2023.10.006. Epub 2023 Oct 20.
6
Changes in REVEAL risk score in patients with pulmonary arterial hypertension treated with macitentan in clinical practice: results from the PRACMA study.在临床实践中，使用马西替坦治疗肺动脉高压患者的 REVEAL 风险评分变化：PRACMA 研究结果。
BMC Pulm Med. 2020 Jun 2;20(1):154. doi: 10.1186/s12890-020-01197-5.
7
[Dynamics of the clinical functional and hemodynamic profile of patients with pulmonary arterial hypertension with initial monotherapy with endothelin receptor antagonists: bosentan vs. macitentan].[肺动脉高压患者初始单药使用内皮素受体拮抗剂治疗的临床功能和血流动力学概况动态变化：波生坦与马昔腾坦对比]
Kardiologiia. 2020 Aug 11;60(7):28-35. doi: 10.18087/cardio.2020.7.n1136.
8
Macitentan for the treatment of portopulmonary hypertension (PORTICO): a multicentre, randomised, double-blind, placebo-controlled, phase 4 trial.马西替坦治疗门脉肺高压（PORTICO）：一项多中心、随机、双盲、安慰剂对照的 4 期临床试验。
Lancet Respir Med. 2019 Jul;7(7):594-604. doi: 10.1016/S2213-2600(19)30091-8. Epub 2019 Jun 6.
9
A Bayesian Network Meta-analysis of Add-on Drug Therapies Specific for Pulmonary Arterial Hypertension.贝叶斯网络荟萃分析肺动脉高压特定附加药物治疗。
Ann Pharmacother. 2020 May;54(5):423-433. doi: 10.1177/1060028019888760. Epub 2019 Nov 18.
10
Long-term treatment of pulmonary arterial hypertension with macitentan in Japanese patients.日本患者的马西替坦治疗肺动脉高压的长期疗效。
Curr Med Res Opin. 2020 Jun;36(6):921-928. doi: 10.1080/03007995.2020.1756234. Epub 2020 May 12.

引用本文的文献

1
Exploring Providers' Behaviors, Attitudes, and Preferences on the Treatment of Pulmonary Arterial Hypertension With Endothelin Receptor Antagonist (ERA) + Phosphodiesterase-5 Inhibitors (PDE5i).探索医疗服务提供者在使用内皮素受体拮抗剂（ERA）联合磷酸二酯酶-5抑制剂（PDE5i）治疗肺动脉高压方面的行为、态度和偏好。
Pulm Circ. 2025 Jun 22;15(2):e70113. doi: 10.1002/pul2.70113. eCollection 2025 Apr.
2
Patient Perspectives on Fixed Dose Combination Therapy for Pulmonary Arterial Hypertension: Exploratory Focus Group Research.肺动脉高压患者对固定剂量联合治疗的看法：探索性焦点小组研究
Pulm Circ. 2025 May 28;15(2):e70098. doi: 10.1002/pul2.70098. eCollection 2025 Apr.
3
Macitentan and Tadalafil Combination Therapy in Patients with Pulmonary Arterial Hypertension and Cardiovascular Comorbidities: Real-World Evidence from OPUS and OrPHeUS.马昔腾坦与他达拉非联合治疗肺动脉高压合并心血管疾病患者：来自OPUS和OrPHeUS的真实世界证据
Adv Ther. 2025 May 19. doi: 10.1007/s12325-025-03180-0.
4
Impact of treatment escalation on rehospitalization among patients with pulmonary arterial hypertension.治疗升级对肺动脉高压患者再住院率的影响。
Sci Rep. 2025 Apr 10;15(1):12235. doi: 10.1038/s41598-025-90975-4.
5
Shifting Paradigms in the Management of Pulmonary Hypertension.肺动脉高压管理中的范式转变
Eur Cardiol. 2024 Dec 23;19:e25. doi: 10.15420/ecr.2024.11. eCollection 2024.
6
Safety, tolerability, and efficacy of an in-class combination therapy switch from bosentan plus sildenafil to ambrisentan plus tadalafil in children with pulmonary arterial hypertension.肺动脉高压患儿从波生坦加西地那非转换为安立生坦加他达拉非的课堂内联合治疗方案的安全性、耐受性及疗效
Pulm Circ. 2024 Dec 26;14(4):e70011. doi: 10.1002/pul2.70011. eCollection 2024 Oct.
7
Macitentan and Tadalafil Combination Therapy in Incident and Prevalent Pulmonary Arterial Hypertension: Real-World Evidence from the OPUS/OrPHeUS Studies.马西替坦与他达拉非联合治疗新发和持续性肺动脉高压的真实世界证据：来自 OPUS/OrPHeUS 研究。
Adv Ther. 2024 Nov;41(11):4205-4227. doi: 10.1007/s12325-024-02964-0. Epub 2024 Sep 24.
8
Initial combination therapy with macitentan and tadalafil in patients with pulmonary arterial hypertension, with and without cardiac comorbidities.马昔腾坦与他达拉非初始联合治疗肺动脉高压患者，伴或不伴有心脏合并症。
Eur J Heart Fail. 2024 Nov;26(11):2379-2391. doi: 10.1002/ejhf.3319. Epub 2024 Jul 5.
9
Survival in systemic sclerosis associated pulmonary arterial hypertension in the current treatment era-results from a nationwide study.当前治疗时代系统性硬化症相关肺动脉高压的生存率——一项全国性研究的结果
Clin Rheumatol. 2024 Jun;43(6):1919-1925. doi: 10.1007/s10067-024-06961-0. Epub 2024 Apr 27.
10
Current Management and Future Directions for Pulmonary Arterial Hypertension Associated with Congenital Heart Disease.先天性心脏病相关肺动脉高压的当前管理与未来方向
J Pers Med. 2023 Dec 20;14(1):5. doi: 10.3390/jpm14010005.

本文引用的文献

1
Risk stratification and medical therapy of pulmonary arterial hypertension.肺动脉高压的风险分层与药物治疗。
Eur Respir J. 2019 Jan 24;53(1). doi: 10.1183/13993003.01889-2018. Print 2019 Jan.
2
Macitentan in Pulmonary Arterial Hypertension: A Focus on Combination Therapy in the SERAPHIN Trial.马西替坦治疗肺动脉高压：SERAPHIN 试验中联合治疗的重点。
Am J Cardiovasc Drugs. 2018 Feb;18(1):1-11. doi: 10.1007/s40256-017-0260-1.
3
Initial tadalafil and ambrisentan combination therapy in pulmonary arterial hypertension: cLinical and haemodYnamic long-term efficacy (ITALY study).初始他达拉非和安贝生坦联合治疗肺动脉高压：临床和血液动力学长期疗效（ITALY 研究）。
J Cardiovasc Med (Hagerstown). 2018 Jan;19(1):12-17. doi: 10.2459/JCM.0000000000000590.
4
Influence of various therapeutic strategies on right ventricular morphology, function and hemodynamics in pulmonary arterial hypertension.各种治疗策略对肺动脉高压患者右心室形态、功能和血流动力学的影响。
J Heart Lung Transplant. 2018 Mar;37(3):365-375. doi: 10.1016/j.healun.2017.08.009. Epub 2017 Aug 26.
5
Risk assessment, prognosis and guideline implementation in pulmonary arterial hypertension.肺动脉高压的风险评估、预后和指南实施。
Eur Respir J. 2017 Aug 3;50(2). doi: 10.1183/13993003.00889-2017. Print 2017 Aug.
6
Upfront combination therapy reduces right ventricular volumes in pulmonary arterial hypertension. upfront 联合治疗可降低肺动脉高压患者的右心室容积。
Eur Respir J. 2017 Jun 29;49(6). doi: 10.1183/13993003.00007-2017. Print 2017 Jun.
7
Initial dual oral combination therapy in pulmonary arterial hypertension.肺动脉高压的初始双联口服联合治疗。
Eur Respir J. 2016 Jun;47(6):1727-36. doi: 10.1183/13993003.02043-2015. Epub 2016 Mar 17.
8
2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT).2015年欧洲心脏病学会（ESC）/欧洲呼吸学会（ERS）肺动脉高压诊断和治疗指南：欧洲心脏病学会（ESC）和欧洲呼吸学会（ERS）肺动脉高压诊断和治疗联合工作组：得到以下组织认可：欧洲儿科和先天性心脏病协会（AEPC）、国际心肺移植学会（ISHLT）。
Eur Heart J. 2016 Jan 1;37(1):67-119. doi: 10.1093/eurheartj/ehv317. Epub 2015 Aug 29.
9
2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT).2015 ESC/ERS 肺动脉高压诊断与治疗指南：欧洲心脏病学会（ESC）和欧洲呼吸学会（ERS）肺动脉高压诊断与治疗工作组制定：该指南得到了欧洲儿科和先天性心脏病协会（AEPC）以及国际心肺移植学会（ISHLT）的认可。
Eur Respir J. 2015 Oct;46(4):903-75. doi: 10.1183/13993003.01032-2015. Epub 2015 Aug 29.
10
Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension.初始使用安贝生坦联合他达拉非治疗肺动脉高压。
N Engl J Med. 2015 Aug 27;373(9):834-44. doi: 10.1056/NEJMoa1413687.

马昔腾坦与他达拉非联合治疗肺动脉高压。

Initial combination therapy of macitentan and tadalafil in pulmonary arterial hypertension.

机构信息

APHP, National Reference Centre for Pulmonary Hypertension, Dept of Respiratory and Intensive Care Medicine, Bicêtre Hospital, University Paris-Sud - University Paris Saclay, INSERM UMR_S999, Le Kremlin-Bicêtre, France

National Reference Centre for Rare Pulmonary Diseases, Dept of Pneumology, Louis Pradel Hospital, Claude Bernard University Lyon 1, UMR754, Lyon, France.

出版信息

Eur Respir J. 2020 Sep 3;56(3). doi: 10.1183/13993003.00673-2020. Print 2020 Sep.

DOI:10.1183/13993003.00673-2020
PMID:32350101
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7469971/
Abstract

https://bit.ly/3aWZagH

摘要

https://bit.ly/3aWZagH